Logo image
Recent advances in oligonucleotide therapeutics in oncology
Journal article   Open access   Peer reviewed

Recent advances in oligonucleotide therapeutics in oncology

H. Xiong, R.N. Veedu and S.D. Diermeier
International Journal of Molecular Sciences, Vol.22(7), Article 3295
2021
pdf
Oligonucleotide.pdfDownloadView
Published (Version of Record) Open Access
url
Free to Read *No subscription requiredView

Abstract

Cancer is one of the leading causes of death worldwide. Conventional therapies, including surgery, radiation, and chemotherapy have achieved increased survival rates for many types of cancer over the past decades. However, cancer recurrence and/or metastasis to distant organs remain major challenges, resulting in a large, unmet clinical need. Oligonucleotide therapeutics, which include antisense oligonucleotides, small interfering RNAs, and aptamers, show promising clinical outcomes for disease indications such as Duchenne muscular dystrophy, familial amyloid neuropathies, and macular degeneration. While no approved oligonucleotide drug currently exists for any type of cancer, results obtained in preclinical studies and clinical trials are encouraging. Here, we provide an overview of recent developments in the field of oligonucleotide therapeutics in oncology, review current clinical trials, and discuss associated challenges.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Metrics

63 File views/ downloads
89 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
2 Chemistry
2.170 Nucleic Acids Chemistry
2.170.988 Oligonucleotide Modifications
Web Of Science research areas
Biochemistry & Molecular Biology
Chemistry, Multidisciplinary
ESI research areas
Chemistry
Logo image